Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009 (2009), Article ID 121458, 10 pages
http://dx.doi.org/10.1155/2009/121458
Research Article

Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy Idaho, Biomedical Research Institute, Idaho State University, Pocatello, ID 83209, USA

Received 24 June 2009; Revised 3 November 2009; Accepted 10 November 2009

Academic Editor: Bruno Vincenzi

Copyright © 2009 Vikas Sehdev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cancer Facts and Figures, American Cancer Society, 2008.
  2. S. A. Hussain, D. H. Palmer, D. Spooner, and D. W. Rea, “Molecularly targeted therapeutics for breast cancer,” BioDrugs, vol. 21, no. 4, pp. 215–224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Harris, H. Fritsche, R. Mennel et al., “American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5287–5312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  5. K. Polyak, “On the birth of breast cancer,” Biochimica et Biophysica Acta, vol. 1552, no. 1, pp. 1–13, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Doyle and K. D. Miller, “Development of new targeted therapies for breast cancer,” Breast Cancer, vol. 15, no. 1, pp. 49–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Silva and M. A. Shupnik, “Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance,” Molecular Endocrinology, vol. 21, no. 7, pp. 1499–1512, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Peppercorn, C. M. Perou, and L. A. Carey, “Molecular subtypes in breast cancer evaluation and management: divide and conquer,” Cancer Investigation, vol. 26, no. 1, pp. 1–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Rodenhuis, M. Bontenbal, Q. G. C. M. van Hoesel et al., “Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer,” Annals of Oncology, vol. 17, no. 4, pp. 588–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Yarden, “Biology of HER2 and its importance in breast cancer,” Oncology, vol. 61, supplement 2, pp. 1–13, 2001. View at Google Scholar · View at Scopus
  12. M. D. Sternlicht, “Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis,” Breast Cancer Research, vol. 8, no. 1, article 201, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar · View at Scopus
  14. B. A. Mincey, “Genetics and the management of women at high risk for breast cancer,” Oncologist, vol. 8, no. 5, pp. 466–473, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Uauy and N. Solomons, “Diet, nutrition, and the life-course approach to cancer prevention,” Journal of Nutrition, vol. 135, no. 12, supplement, pp. 2934S–2945S, 2005. View at Google Scholar · View at Scopus
  16. P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002. View at Google Scholar · View at Scopus
  17. D. M. Parkin, “Cancers of the breast, endometrium and ovary: geographic correlations,” European Journal of Cancer and Clinical Oncology, vol. 25, no. 12, pp. 1917–1925, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. A. C. Society, Cancer Facts and Figures, American Cancer Society, 2006.
  19. R. G. Ziegler, R. N. Hoover, M. C. Pike et al., “Migration patterns and breast cancer risk in Asian-American women,” Journal of the National Cancer Institute, vol. 85, no. 22, pp. 1819–1827, 1993. View at Google Scholar · View at Scopus
  20. R. Doll and R. Peto, “The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today,” Journal of the National Cancer Institute, vol. 66, no. 6, pp. 1191–1308, 1981. View at Google Scholar · View at Scopus
  21. W. C. Willett, “Diet, nutrition, and avoidable cancer,” Environmental Health Perspectives, vol. 103, supplement 8, pp. 165–170, 1995. View at Google Scholar · View at Scopus
  22. W. C. Willett, “Diet and cancer,” Oncologist, vol. 5, no. 5, pp. 393–404, 2000. View at Google Scholar · View at Scopus
  23. X. Cui, Q. Dai, M. Tseng, X.-O. Shu, Y.-T. Gao, and W. Zheng, “Dietary patterns and breast cancer risk in the Shanghai breast cancer study,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 7, pp. 1443–1448, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. H. Do, S. S. Lee, J. Y. Kim, P. J. Jung, and M. H. Lee, “Fruits, vegetables, soy foods and breast cancer in pre- and postmenopausal korean women: a case-control study,” International Journal for Vitamin and Nutrition Research, vol. 77, no. 2, pp. 130–141, 2007. View at Google Scholar · View at Scopus
  25. A. H. Wu, M. C. Yu, C.-C. Tseng, F. Z. Stanczyk, and M. C. Pike, “Dietary patterns and breast cancer risk in Asian American women,” American Journal of Clinical Nutrition, vol. 89, no. 4, pp. 1145–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Q. Dai, A. A. Franke, H. Yu et al., “Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 6, pp. 497–502, 2003. View at Google Scholar · View at Scopus
  27. M. Iwasaki, M. Inoue, T. Otani et al., “Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1677–1683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Verheus, C. H. van Gils, L. Keinan-Boker, P. B. Grace, S. A. Bingham, and P. H. M. Peeters, “Plasma phytoestrogens and subsequent breast cancer risk,” Journal of Clinical Oncology, vol. 25, no. 6, pp. 648–655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. A. Pop, L. M. Fischer, A. D. Coan, M. Gitzinger, J. Nakamura, and S. H. Zeisel, “Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial,” Menopause, vol. 15, no. 4, pp. 684–692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Balabhadrapathruni, T. J. Thomas, E. J. Yurkow, P. S. Amenta, and T. Thomas, “Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells,” Oncology Reports, vol. 7, no. 1, pp. 3–12, 2000. View at Google Scholar · View at Scopus
  31. A. I. Constantinou, A. E. Krygier, and R. R. Mehta, “Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice,” American Journal of Clinical Nutrition, vol. 68, no. 6, supplement, pp. 1426S–1430S, 1998. View at Google Scholar · View at Scopus
  32. Z. Jin and R. S. MacDonald, “Soy isoflavones increase latency of spontaneous mammary tumors in mice,” Journal of Nutrition, vol. 132, no. 10, pp. 3186–3190, 2002. View at Google Scholar · View at Scopus
  33. M. Katdare, M. Osborne, and N. T. Telang, “Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells,” International Journal of Oncology, vol. 21, no. 4, pp. 809–815, 2002. View at Google Scholar · View at Scopus
  34. M. S. Sakla, N. S. Shenouda, P. J. Ansell, R. S. MacDonald, and D. B. Lubahn, “Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells,” Endocrine, vol. 32, no. 1, pp. 69–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. N. B. Kumar, A. Cantor, K. Allen, D. Riccardi, and C. E. Cox, “The specific role of isoflavones on estrogen metabolism in premenopausal women,” Cancer, vol. 94, no. 4, pp. 1166–1174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. R. D. Snyder and P. J. Gillies, “Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells,” Environmental and Molecular Mutagenesis, vol. 40, no. 4, pp. 266–276, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Michael McClain, E. Wolz, A. Davidovich, and J. Bausch, “Genetic toxicity studies with genistein,” Food and Chemical Toxicology, vol. 44, no. 1, pp. 42–55, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. R. D. Snyder and P. J. Gillies, “Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids,” Food and Chemical Toxicology, vol. 41, no. 10, pp. 1291–1298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. J. Moon, D. A. Brazeau, and M. E. Morris, “Effects of flavonoids genistein and biochanin A on gene expression and their metabolism in human mammary cells,” Nutrition and Cancer, vol. 57, no. 1, pp. 48–58, 2007. View at Google Scholar · View at Scopus
  40. T. L. Johnson, M. B. Lai, J. C. Lai, and A. Bhushan, “Inhibition of cell proliferation and MAP kinase and Akt pathways in oral squamous cell carcinoma by genistein and biochanin A,” Evidence-Based Complementary and Alternative Medicine. View at Publisher · View at Google Scholar
  41. M. Lacroix and G. Leclercq, “Relevance of breast cancer cell lines as models for breast tumours: an update,” Breast Cancer Research and Treatment, vol. 83, no. 3, pp. 249–289, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Zientek-Targosz, D. Kunnev, L. Hawthorn et al., “Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors,” Molecular Cancer, vol. 7, article 51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Debnath, S. K. Muthuswamy, and J. S. Brugge, “Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures,” Methods, vol. 30, no. 3, pp. 256–268, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Ueda, S. Wang, N. Dumont, J. Y. Yi, Y. Koh, and C. L. Arteaga, “Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor β-induced cell motility,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 24505–24513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. J. S. Ross, J. A. Fletcher, G. P. Linette et al., “The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy,” Oncologist, vol. 8, no. 4, pp. 307–325, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. H. D. Soule, T. M. Maloney, S. R. Wolman et al., “Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10,” Cancer Research, vol. 50, no. 18, pp. 6075–6086, 1990. View at Google Scholar · View at Scopus
  47. O. W. Petersen, L. Ronnov-Jessen, A. R. Howlett, and M. J. Bissell, “Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 19, pp. 9064–9068, 1992. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Adeyinka, Y. Nui, T. Cherlet, L. Snell, P. H. Watson, and L. C. Murphy, “Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression,” Clinical Cancer Research, vol. 8, no. 6, pp. 1747–1753, 2002. View at Google Scholar · View at Scopus
  49. M. Osaki, M. Oshimura, and H. Ito, “PI3K-Akt pathway: its functions and alterations in human cancer,” Apoptosis, vol. 9, no. 6, pp. 667–676, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. M. M. Mita, A. Mita, and E. K. Rowinsky, “Mammalian target of rapamycin: a new molecular target for breast cancer,” Clinical Breast Cancer, vol. 4, no. 2, pp. 126–137, 2003. View at Google Scholar · View at Scopus
  51. K. M. Ahmed, N. Cao, and J. J. Li, “HER-2 and NF-κB as the targets for therapy-resistant breast cancer,” Anticancer Research, vol. 26, no. 6B, pp. 4235–4243, 2006. View at Google Scholar · View at Scopus
  52. V. Chabottaux and A. Noel, “Breast cancer progression: insights into multifaceted matrix metalloproteinases,” Clinical and Experimental Metastasis, vol. 24, no. 8, pp. 647–656, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. M. M. Moasser, “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene, vol. 26, no. 45, pp. 6469–6487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. S.-J. Su, M.-D. Lai, T.-M. Yeh, and N.-H. Chow, “Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones,” European Journal of Cancer, vol. 37, no. 11, pp. 1413–1418, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Akiyama, J. Ishida, S. Nakagawa et al., “Genistein, a specific inhibitor of tyrosine-specific protein kinases,” Journal of Biological Chemistry, vol. 262, no. 12, pp. 5592–5595, 1987. View at Google Scholar · View at Scopus
  56. D. Bernhard, W. Schwaiger, R. Crazzolara, I. Tinhofer, R. Kofler, and A. Csordas, “Enhanced MTT-reducing activity under growth inhibition by resveratrol in CEM-C7H2 lymphocytic leukemia cells,” Cancer Letters, vol. 195, no. 2, pp. 193–199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. C. Pagliacci, F. Spinozzi, G. Migliorati et al., “Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival,” European Journal of Cancer, Part A, vol. 29, no. 11, pp. 1573–1577, 1993. View at Google Scholar · View at Scopus
  58. K. A. Rasbach and R. G. Schnellmann, “Isoflavones promote mitochondrial biogenesis,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 536–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. F. D. Ragione, V. Cucciolla, A. Borriello et al., “Resveratrol arrests the cell division cycle at S/G2 phase transition,” Biochemical and Biophysical Research Communications, vol. 250, no. 1, pp. 53–58, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. M. J. Messina and C. E. Wood, “Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary,” Nutrition Journal, vol. 7, article 17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. V. S. Sivaraman, H.-Y. Wang, G. J. Nuovo, and C. C. Malbon, “Hyperexpression of mitogen-activated protein kinase in human breast cancer,” Journal of Clinical Investigation, vol. 99, no. 7, pp. 1478–1483, 1997. View at Google Scholar · View at Scopus
  62. C. Xing and W. Imagawa, “Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF,” Carcinogenesis, vol. 20, no. 7, pp. 1201–1208, 1999. View at Publisher · View at Google Scholar · View at Scopus
  63. K. L. Dunn, P. S. Espino, B. Drobic, S. He, and J. R. Davie, “The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling,” Biochemistry and Cell Biology, vol. 83, no. 1, pp. 1–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Pianetti, M. Arsura, R. Romieu-Mourez, R. J. Coffey, and G. E. Sonenshein, “Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN,” Oncogene, vol. 20, no. 11, pp. 1287–1299, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma, “Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis,” Clinical Cancer Research, vol. 10, no. 22, pp. 7621–7628, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. J.-T. Hsu, H.-C. Hung, C.-J. Chen, W.-L. Hsu, and C. Ying, “Effects of the dietary phytoestrogen biochanin A on cell growth in the mammary carcinoma cell line MCF-7,” Journal of Nutritional Biochemistry, vol. 10, no. 9, pp. 510–517, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. J. Moon, B. S. Shin, G. An, and M. E. Morris, “Biochanin A inhibits breast cancer tumor growth in a murine xenograft model,” Pharmaceutical Research, vol. 25, no. 9, pp. 2158–2163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Yang, S. M. Edgerton, S. D. Kosanke et al., “Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice,” Cancer Research, vol. 63, no. 10, pp. 2425–2433, 2003. View at Google Scholar · View at Scopus